13.07.2015 Views

Prise en charge de l'OAP cardiogénique

Prise en charge de l'OAP cardiogénique

Prise en charge de l'OAP cardiogénique

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Traitem<strong>en</strong>t médical :• « Randomised trial of high –doseisosorbi<strong>de</strong> dinitrate plus low-dosefurosemi<strong>de</strong> versus high-dosefurosemi<strong>de</strong> plus low-dose isosorbi<strong>de</strong>dinitrate in severe pulmonary oe<strong>de</strong>ma»Cotter et coll :The Lancet 1998;351:389-393• Etu<strong>de</strong> prospective• 110 Pati<strong>en</strong>ts avec OAP sevère +saturation <strong>en</strong> O2 = 90 %• Sous 02 :10 l/ min• Résultats :• Groupe A (56 ):◦ isosorbi<strong>de</strong> dinitrate 3mg<strong>en</strong> bolus toutes les 5 min+ 40 mg <strong>de</strong> furosemi<strong>de</strong>• Groupe B (54) :◦ 80 mg <strong>de</strong> furo IV toutesles 15 min + isosorbi<strong>de</strong> 1mg/h à augm<strong>en</strong>ter <strong>de</strong>1mg toutes les 10 min• Poursuite du traitem<strong>en</strong>tjusqu’à saturation > 96 %ou baisse <strong>de</strong> PA <strong>de</strong> 30 %ou sous 9O mmhg

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!